Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

“…The GETUG-12 trial identified improved relapse free, but not prostate cancer specific or overall survival [ 17 ]. Similar findings were noted in the STAMPEDE trial, although the Kaplan–Meier curves separated in favour of a combination of ADT and abiraterone over ADT alone [ 18 ]. In the mCRPC setting the improvement in long-term survival with chemotherapy is measured in months, although occasional anecdotal long-term suppression of cancer is well known to clinicians.…”

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

“…This finding contrasts with those that show that docetaxel improves the survival of metastatic patients but, for highrisk non-metastatic patients, although it delays relapsefree survival, it does not have a benefit in terms of metastasis-free or overall survival. [14][15][16] The proportion of metastasis-free survival events in the primary outcome measure that were attributed to metastasis and of deaths attributed to prostate cancer were lower in the combination-therapy groups. These results might suggest that, by preventing relapse and death from prostate cancer, patients treated with combination therapy are more likely to live longer and die from another cause.…”

“…[7][8][9][10][11][12][13] However, to date, none of these drugs has demonstrated a clear and consistent improvement in the survival of patients with non-metastatic prostate cancer starting long-term ADT. [14][15][16] Abiraterone acetate (hereafter referred to as abiraterone) is a selective, irreversible inhibitor of CYP17, which results in more effective androgen depletion than ADT alone. 17 It is combined with prednisone to reduce side-effects of mineralocorticoid excess.…”

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)

“…Neither study demonstrated a role for docetaxel for men with high-risk BCR following prostatectomy with or without postoperative RT. STAM-PEDE demonstrated a benefit to the use of docetaxel for all castration-sensitive disease, but the BCR population was under-represented [21,22].…”